A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms KEYNOTE-021
- Sponsors Merck Sharp & Dohme
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 12 Jul 2021 Results of a post-hoc retrospective pooled exploratory analysis from three clinical studies: KEYNOTE-021 cohort G (nonsquamous), KEYNOTE-189 (nonsquamous), and KEYNOTE-407 (squamous) assessing whether baseline brain metastases influenced efficacy published in the Journal of Thoracic Oncology
- 31 Jan 2021 Results of a meta-analysis from seven clinical studies: KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, KEYNOTE-021, CHECKMATE-227, CHECKMATE 026 and MYSTIC presented at the 2020 World Conference on Lung Cancer